论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
淋巴细胞与高密度脂蛋白之比作为炎症和代谢综合征的新指标
Authors Chen H, Xiong C, Shao X, Ning J, Gao P, Xiao H, Chen Y, Zou Z, Hong G, Li X, Shao M, Sheng J, Yang X, You X, Zou H
Received 13 June 2019
Accepted for publication 1 September 2019
Published 14 October 2019 Volume 2019:12 Pages 2117—2123
DOI https://doi.org/10.2147/DMSO.S219363
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Nicola Ludin
Peer reviewer comments 2
Editor who approved publication: Dr Juei-Tang Cheng
Purpose: Metabolic syndrome (MetS), which is a global public health problem, is a state of chronic low-grade inflammation. This study looked at the changes in hematological parameters and the predictive value of the lymphocyte to high-density lipoprotein cholesterol (HDL-C) ratio (LHR) as a new index in subjects with and without MetS in coastal cities in southern China.
Patients and methods: In this cross-sectional study, there were 852 participants (n = 598 with MetS and n = 254 without MetS). MetS was defined in accordance with the National Cholesterol Education Program, Adult Treatment Panel III (NCEP-ATP III) criteria.
Results: MetS was positively correlated with white blood cell count, total lymphocyte count, neutrophil count, red blood cell count, hematocrit, hemoglobin, and high-sensitivity C-reactive protein levels (p <0.05). In addition, there was a positive correlation between LHR and the number of metabolic risk factors for MetS. In a logistic regression analysis, LHR (odds ratio: 4.117; 95% CI: 2.766–6.309; p <0.001) was an independent predictor of MetS. When a receiver operating characteristic (ROC) curve analysis was used to assess the value of LHR for predicting MetS, the area under the curve yielded a cut-off value of 1.657, with a sensitivity of 65% and a specificity of 64% (p <0.0001).
Conclusion: In summary, MetS can involve changes in blood parameters, and LHR may be a useful marker of inflammation to assess the presence and severity of MetS.
Keywords: inflammation, marker, metabolic syndrome, lymphocyte to high-density lipoprotein cholesterol ratio
